Results: Two hundred seventeen NSCLC patients were treated in our center. In fifty cases there was a volume reduction, so a "replanning" was outlined. Patients' characteristics were: mean age 69.6 years (range 38-92), squamous histology 56%, 32% adenocarcinoma, other 12%, stage IIIA 58% and IIIB 42%. The median total dose delivered was 65.7 Gy with standard fractionation. Median CTV at CT simulation and at "replanning" was 125.2 cc and 74.7 cc, respectively, with a median reduction of 43.1%. The "replanning" has been performed at a median dose of 45 Gy. At first follow up, 48 patients were evaluated. Response, according to RECIST criteria, was as follow: 2 complete responses (4.1%), 33 partial responses (68.8%) and 13 stable disease (27.1%). Grade 3 toxicities (CTCAE_4.0) were: acute esophageal in 4% of cases, pulmonary 6% (1 case acute and 2 chronic). With a median follow-up of 20.5 months, there have been 15 local (31%) and 22 distant (46%) failures. The observed local failures were: in field in 20.8% of cases, "marginal" in 6.1% and out of field in 4.1%. The median time to local failure, progression free survival and overall survival were 8.5, 8.3 and 30.5 months, respectively. The median onset of "marginal", in field, out of field and distant failures was 12, 9.2, 7.1 and 7.8 months, respectively.
Purpose or Objective:
To assess the feasibility and safety of combined stereotactic body radiotherapy (SBRT) of the primary tumor (PT) and concurrent chemoradiation (CCRT) in stage III NSCLC, the Hybrid study (single center phase I: NCT01933568) was initiated. Primary endpoint is the mean lung dose (MLD) associated with 15% chance on radiation pneumonitis (RP) ≥ G3 and dyspnea ≥ G3. Secondary endpoints are toxicity and disease control. This is the first report of adverse events observed.
Material and Methods:
Eligible patients had stage III or inoperable stage II NSCLC with a peripheral PT < 5 cm. Patient received CCRT: 24x2.75 Gy or 24x2.42 on the pathological lymph nodes (LN) with daily low dose cisplatinum 6 mg/m2 with an overall treatment time of 32 days. SBRT was delivered in 3 fractions of 14-18 Gy in the 2nd week concurrent with CCRT. If the fractionated LN treatment plan contributed to the PT dose, the total SBRT dose was corrected for accordingly. The MLD was escalated with 2 Gy increments using the Time-to-Event Continuous Reassessment Method (TITE-CRM) statistical design driven by dose limiting toxicity (RP or dyspnea ≥ G3; CTCAE v4) within 12 months post treatment. The range of acceptable SBRT fraction doses allowed accruing patients in different MLD dose bins.
Results: From March 2013-October 2015 12 patients gave informed consent for the trial. One patient was excluded after the 1st week of treatment due to a baseline shift of the PT towards the mediastinum, causing unacceptable dose to the mediastinal organs at risk (OAR) if treated with SBRT. Median follow up (FU) was 8 months (range 0-26), median age was 63 years (range 61-75), 73% was male, 73% had adenocarcinoma, 18% squamous cell carcinoma, 9% large cell NOS. 73% had T1 tumors, 9% T2, 18% T3 (2 tumors), 18% N1, 73% N2 and 9% N3. Ten patients received CCRT, 1 patient radiotherapy only due to co-morbidities. No locoregional recurrences have been observed. Two patients developed distant metastases, one of which died 12 months post treatment due to leptomeningeal metastases. Median SBRT dose was 53 Gy (range 43-54 Gy) and median LN dose was 2.75 Gy. Median MLD (α/β=3 Gy) was 11.9 Gy (range 5.2-18 Gy). In 2 patients SBRT dose was decreased: in 1 patient due to allocation in a lower MLD risk group than the treatment plan MLD, in 1 patient because of normal tissue constraints of the mediastinal OAR. During treatment 4 patient developed dysphagia G2, 2 fatigue G2, 1 thrombocytopenia G2, 1 anorexia G2 and 1 patient hemoptysis G2 . Radiation pneumonitis G2 occurred in 1 patient at 2.5 months FU with an MLD of 12.4 Gy. One patient developed chest wall pain G2 due to a rib fracture at 32 months FU. There were no G3-5 toxicities.
Conclusion:
A Hybrid treatment of SBRT of the primary tumor combined with concurrent chemoradiation is feasible. This phase I trial is currently accruing and no unexpected toxicity has been observed thus far. 
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